广誉远：10月24日召开董事会会议

Group 1 - Company Guangyuyuan (SH 600771) held its 18th meeting of the 8th board of directors on October 24, 2025, via telecommunication to review the Q3 2025 report [1] - For the first half of 2025, Guangyuyuan's revenue composition was as follows: pharmaceutical industry accounted for 89.39%, other businesses 3.85%, and health wine 3.29% [1] - The current market capitalization of Guangyuyuan is 9.4 billion yuan [2] Group 2 - The Chinese innovative drug sector has generated $80 billion in overseas licensing deals this year [2] - The secondary market for biopharmaceuticals is experiencing a boom, while the primary market is facing challenges in fundraising [2]